KAT6A and ovarian carcinoma: An increasing number of studies are exploring the noncatalytic functions of enzymes in addition to their catalytic activity.[35] Here, we demonstrated that the destruction of KAT6A LLPS, rather than catalytic inhibition, increased PARP1 trapping and restored sensitivity to PARPi, providing potential therapeutic strategies for PARPi‐resistant ovarian cancer.